Neoadjuvant Chemotherapy for Breast Cancer: Revisiting the Lymph Node Ratio as a Prognostic Factor NAC for BC
Abstract
N/A
References
Mashoori N, Zand S, Nazemian R, Kaviani A. Effect of the Surgery Type, Mastectomy vs. Breast Conserving Surgery, on Outcomes of Patients With Locally Advanced Breast Cancer Receiving Neoadjuvant Therapy. Arch Breast Cancer. 2017;4(4):129-35. doi: 10.19187/abc.201744129-135.
Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, et al. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2022 Dec;23(12):1517-1524. doi: 10.1016/S1470-2045(22)00613-1.
Rosenberger LH, Ren Y, Thomas SM, Greenup RA, Fayanju OM, Hwang ES, et al. Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough? Breast Cancer Res Treat. 2020 Feb;179(3):661-670. doi: 10.1007/s10549-019-05500-9.
Gangadaran S. Axillary Nodal Examination in Breast Cancer: How Much Is Enough? Evidence for a New Minimum. Arch Breast Cancer. 2016 12/03/2016;3(4):126-129. doi: 10.19187/abc.201634126-129
Erbes T, Orlowska-Volk M, Zur Hausen A, Rücker G, Mayer S, Voigt M, et al. Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection. BMC Cancer. 2014 Jan 3;14. doi: 10.1186/1471-2407-14-4.
Safavi A, Kaviani A, Mohammadzadeh N, Zand S, Elahi A, Krag D. Breast Cancer Prognostication by Pathologic Node Staging (pN-staging) System Versus Lymph Node Ratio (LNR): A Critical Review of Conflicts With Number of Nodes, Z-0011 Trial , Staging Cut-points, Neo-adjuvant Therapy, and Survival Estimation. Arch Breast Cancer. 2017 Dec 10, 2017;4(4):110-123. doi: 10.19187/abc.201744110-123.
Vinh-Hung V, Verkooijen HM, Fioretta G, Neyroud-Caspar I, Rapiti E, Vlastos G, et al. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol. 2009;27(7):1062-1068. doi: 10.1200/JCO.2008.18.6965.
Cho DH, Bae SY, You JY, Kim HK, Chang YW, Choi YJ, et al. Lymph node ratio as an alternative to pN staging for predicting prognosis after neoadjuvant chemotherapy in breast cancer. Kaohsiung J Med Sci. 2018 Jun;34(6):341-347. doi: 10.1016/j.kjms.2017.12.015.
Ai X, Liao X, Wang M, Hu Y, Li J, Zhang Y, et al. Prognostic Value of Lymph Node Ratio in Breast Cancer Patients with Adequate Pathologic Evidence After Neoadjuvant Chemotherapy. Med Sci Monit. 2020 Apr 29;26:e922420. doi: 10.12659/MSM.922420.
De la Cruz-Ku GA, Chambergo-Michilot D, Valcarcel B, Rebaza P, Möller M, Araujo JM, et al. Lymph node ratio as best prognostic factor in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy. Breast J. 2020 Sep;26(9):1659-1666. doi: 10.1111/tbj.13988.
Jung SW, Lim SY, Na YM, et al. Lymph Node Ratio as a Good Prognostic Factor for Patients with Pathologic N3a Breast Cancer with 10 or More Metastatic Axillary Lymph Nodes. J Breast Dis. 2021 12;9(2):56-64.
Tsai J, Bertoni D, Hernandez-Boussard T, et al. Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer. Ann Surg Oncol. 2016 Oct;23(10):3310-6.
Soran A, Ozmen T, Salamat A, et al. Lymph Node Ratio (LNR): Predicting Prognosis after Neoadjuvant Chemotherapy (NAC) in Breast Cancer Patients. Eur J Breast Health. 2019 Oct;15(4):249-255.
Liu J, Li Y, Zhang W, et al. The prognostic role of lymph node ratio in breast cancer patients received neoadjuvant chemotherapy: A dose-response meta-analysis. Front Surg. 2022;9:971030.
Nguyen NP, Vinh-Hung V, Baumert B, et al. Older Cancer Patients during the COVID-19 Epidemic: Practice Proposal of the International Geriatric Radiotherapy Group. Cancers (Basel). 2020 May 19;12(5).
Shubeck S, Zhao F, Howard FM, et al. Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US. JAMA Netw Open. 2023 Mar 1;6(3):e235834.
Authors
Copyright (c) 2023 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.
